As­traZeneca signs com­pu­ta­tion­al drug dis­cov­ery col­lab­o­ra­tion; J&J-part­nered Fate cleared for the clin­ic

→ As­traZeneca has picked out its lat­est com­pu­ta­tion­al part­ner from Toron­to, tap­ping Pro­tein­Qure to ap­ply its struc­ture-based de­sign plat­form for the cre­ation of pep­tide ther­a­peu­tic li­braries. The phar­ma gi­ant is re­spon­si­ble for ex­per­i­men­tal val­i­da­tion of the leads gen­er­at­ed from the col­lab­o­ra­tion.

→ Three months af­ter J&J cast a bright spot­light on Fate’s pi­o­neer­ing stem cell tech­nol­o­gy, the biotech has se­cured clear­ance from the FDA to be­gin a first-in-hu­man study. The Phase I will test an off-the-shelf CAR-T ther­a­py tar­get­ing CD19+ tu­mors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER